Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Block 4 Pharm > Hyperlipidemia Drugs > Flashcards

Hyperlipidemia Drugs Flashcards

You may prefer our related Brainscape-certified flashcards:
WSET ® Level 4 D2 Business of Wine flashcards
1
Q

List the Optimal, borderline and high serum LDL levels

A

Optimal less than 100, borderline 130-159, high 160-189, very high greater than 190mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List the optimal and low serum HDL

A

M >40mg/dL

W >50mg/dL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

List the optimal, borderline and high TG level

A

optimal less than 150, borderline 150-199, high 200-499, very high greater than 500

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

MOA of the statins

A
  1. Analog of HMG-CoA, and competitively inhibits the HMG-CoA Reductase (rate limiting enzyme in cholesterol synthesis)
  2. Reduce hepatic cholesterol synthesis and triggers induction of SREBP transcription factor
  3. SREBP increase the expression of the LDL-R and increases clearance of serum LDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

MOA of the Bile Acid Binding Resins

A
  1. Bind to bile acid and prevent their reabsorption in the small intestines
  2. Increased bile acid production (upreg. cholesterol 7a hydroxylase) - decreasing hepatic cholesterol conc
  3. Triggers up regulation of the LDL-R and increased LDL clearance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the 2 drugs in the PCSK9

A

Evolocumab, Alirocumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What drugs can be used for familial hyercholestolemia

A

heterozygous FH (PSCK9 inhibitors), Ezetimibe (Cholesterol Absorption Inhbitor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Indications for the Statins

A

drug of choice for treating patients with increased LDL-C, drug of choice for both primary and secondary prevention of CHD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What statin would be not contraindicated in a patient liver disease or taking other medications metabolized by the CYP450 system

A

Pravastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

For a patient with cardiovascular risk what are the preferred lipoprotein goals

A

LDL > 190mg/dL (or >70mg/dL with Diabetes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Contraindications of the Stains

A

Pregnancy and Severe liver disease (except pravastatin - hepatic/elimination)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Clinical effects of Niacin

A

leads to a significant decrease in TGs (30-80%), mild decrease in LDLs (10-20%) and mild increase in HDLs (10-30%)* most effective at raising HDLs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Indications for Bile Acid Binding Resins

A

2nd line agent due to efficacy of STATIN, can be used in combo with statin, can be used in patients for whom statin are either not effective or contraindicated, drug of choice for treating hypercholesterolemia in children & women who are lactating or pregnant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List the statin drugs

A

Atorvastatin, Fluvastatin, Lovastatin, Simavastatin, Pravastatin, Rosuvastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MOA of Ezetimide

A

Inhibitor of NPCIL1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What 3 drugs are the Bile Acid binding resins

A

Cholestryamine, Colestipoli, Colesevelan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Contraindications of the Bile Acid Binding Resins

A

type III dysbetalipoproteinemia and raised TGs (>400mg/dL) due to risk of further increasing VLDL levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the 2 fibrate drug

A

Gemfibrozil and Fenofibrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Adverse Effects of the statin

A

RHABDOMYOLYSIS, muscle myalgia/myopathy, GI disturbance, increase liver enzymes, small increase in risk of T2DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Adverse Effects of the bile acid-binding resins

A

Not absorbed or metabolized and therefore very safe and few side effects, GI disturbances, at high con, Cholestyramine and Colestipol impair the absorption of Vit. A, D, E, and K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Drug interactions with the BAB Resins

A

Cholestyramine and Colestipol (not Colesevelam) interfere with the absorption of MANY drugs (tetracyline, penicillin, vancomycin, phenobarbital, digoxin, warfarin, propanalol, parvastatin, fluvastatin, aspirin, and thiazide diurectics)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Effect of Statins on cholesterol

A

Significant reduction in LDL (20-60%), modest reduction in TGs (10-20%) and modest increase in HDL (5-10%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Other activities of statins that contribute to anti-atherogenic effects

A

Inhibits adhesion molecule expression on endothelium, inhibts adhesion of monocytes to the endothelium, inhibits monocyte prolix and migration, inhibits oxidation of LDLs (foam cell formation), inhibits SMC prolif., Inhibits inflammatory responses, and stabilizes the endothelium (reduced plaque rupture risk)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What drugs interaction with the statins increase the incidence of rhadomyolysis

A

inhibitors of CYP3A4 (cyclosporin, macrolide abx, ketaconazole)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How do the therapeutic benefits increase when the dose of Statins is increased

A

Double or quadrupling the statin dose usually results in ONLT a modest (5-6%) further decease in LDL and significantly increases the potential for AEs

26
Q

How are Statins take up into the liver

A

OATP2

27
Q

How are most statins metabolized

A

Glucoronidated by glucurornyl transferase enzymes and the

CYP450 system

28
Q

Which statin are metabolized by CYP3A4

A

Lovastatin, Simvastatin, Atorvastatin (grapefruit juice interaction)

29
Q

Which statin are metabolized by CYP2C9

A

Fluvastatin and Rosuvastatin

30
Q

Which statin is metabolized by CYP2C19

A

Rosuvastatin

31
Q

Which statin is NOT metabolized by the CYP450 system

A

Pravastatin

32
Q

CYP3A4 inhibitors (Cyclosporin, Ritonavir, Intraconazole, and Erythromycin) will increase levels of which statins

A

Lovastatin, Simvastatin and Atorvastatin

33
Q

CYP2C9 inhibitors will increase levels of which statin

A

Fluvastatin and Rosuvastatin

34
Q

Which statin is the drug of choice for a transplant patient treated with cyclosporin

A

Pravastatin is NOT metabolized by P450 enzymes

35
Q

How does gemfibrozil interact with statin metabolism

A
  1. inhibits OATP2 tranporter mediated uptake of statins in to the liver
  2. inhibits the glucoronidation of statin (which is involved in the metabolism and ultimate excretion of ALL statin drugs)
36
Q

MOA of cholesterol absorption inhibitors (Ezetimibe)

A
  1. inhibits action of NPC1L1 involved in the absorption of dietary and biliary cholesterol in the small intestines
  2. reduced cholesterol results in decreased delivery to the liver reducing VLDL and LDL production and LDLR
37
Q

Clinical Effect of Ezetimibe

A

Reduces LDL-C, minimal effect on HDL and TGs (does not raise TGs)

38
Q

What effect does Ezetimibe have when administered with a statin

A

further 25% reduction in LDL than with Statin alone (allows the use of a lower statin dose to avoid adverse effects)

39
Q

Indication for Ezetimibe

A

Primary hypercholesterolemia (esp with Statin) and FH

40
Q

Adverse effects of Ezetimibe

A

GI disturbance

41
Q

MOA of alirocumab and evolocumab

A

Inhibitor of PCSK9 (binds to PCSK9 and prevents its binding to the LDLR there by preventing the LDLR from degradation and) and increases LDLR on the cell surface

42
Q

Indications for alirocumab and evolocumab

A

heterozygous FH and patients that have not achieved goals with maximally tolerated statins

43
Q

MOA of Lomitapide

A

Inhibitor of MTP (micosomal triglyceride transfer protein), which is required for the assembly of chylomicrons and VLDLs

44
Q

Indication for Lomitapide

A

homozygous FH

45
Q

MOA of Mipomersen

A

Antisense oligonucleotide for apoB (48,100), reduced expression of apoB resulting in reduced production of VLDLs and lower levels of LDLs

46
Q

What is a major risk of TGs >500mg/dL

A

pancreatitis

47
Q

MOA of Niacin

A

Very complex: 1. decreases lipolysis in adipocytes leads to a decrease in FFA and a decrease in VLDL. 2. inhibits DGAT2 leading to decreases VLDL synth. 3. decreases apoCIII (LPL inhibitor) and thus enhances LPL leading to VLDL. 4. increases apoA1 expression leading to increased HDL production. 5. decreases Lp(a) leading to decrease in thrombosis

48
Q

What is the best treatment option for a patient with TG level of 175mg/dL

A

when TGs are borderline high (150-199mg/dL) a lifestyle change is indicated, low fat diet, exercise & cessation of smoking/alcohol

49
Q

Adverse effects of Niacin

A

SKIN FLUSHING, inhibits tubular secretion of URIC ACID (predispose to GOUT), exacerbate PEPTIC ULCER DISEASE, GI disturbance, modest hyperglycemia in T2DM, rare hepatic toxicity

50
Q

Contraindications of Niacin

A

Peptic ulcer disease, pt. with history of gout, caution with diabetics and pts with impaired liver function

51
Q

What is the clinical effects of the fibrates (Fenofibrate and Gemfibrozil)

A

Significant reduction in TGs (40-60%), mild reduction in LDLs (10-20%), and mild increase in HDL (10-20%)

52
Q

MOA of Fenofibrate and Gemfibrozil

A

activate PPARa to promote the expression of genes involved in lipoprotein, function and metabolism (increase apoA1, apoAII (increasing HDL), decreases ApoCIII increasing LPL (decreases TGs)

53
Q

Indications for Fenofibrate and Gemfibrozil

A

hypertriglyceridemia associated with low HDL and therapy of choice for patients with familial dysbetalipoproteinemia/Type III hyperlipoproteinemia, TG levels greater than 500mg/dL

54
Q

Adverse effects of the fenofibrate and gemfibrozil

A

Increased predisposition to GALLSTONES, myopathy/rhadomyolysis leading to acute renal failure (v. rare - a lot more common with gemfibrozil vs fenofibrate, esp with given with high dose of statin), hepatitis, GI disturbance

55
Q

Drug interaction with the fenofibrate and gemfibrozil

A

STONG PROTEIN BINDERS and can displace other prot. bound drugs from albumin resulting in increase conc (warfarin, sulfonyureas)

56
Q

why in fenofibrate preferred over gemfibrozil when given in combination with a statin

A

genfibrozil inhibits OATP2 and glucoronidation (fenofibrate does not), and can increase serum contents of statins and increased risk of myopathy and rhabdmyolysis

57
Q

Contraindication for fenofibrate and gemibrozil

A
  1. pregnant/lactating women, 2. pt with severe hepatic dysfunction, 3. Pt with severe renal dysfunction, 4. pts with preexisting gall bladder disease
58
Q

What are eicosapentaenoic acid and docosahexaenoic acid

A

Fish oils: omega-3 long chain polyunsaturated fatty acids

59
Q

clinical effect of fish oils (eicosapentaenoic acid and docosahexaenoic acid)

A

lowers serum TGs (30-50%), minor HDL increase, can increase LDL in some patients

60
Q

Indication for fish oils (eicosapentaenoic acid and docosahexaenoic acid)

A

ONLY as an adjunct to diet in the treatment of high TGs in pt with TG level >500mg/dL

61
Q

MOA of fish oils (eicosapentaenoic acid and docosahexaenoic acid)

A

unclear: inhibiting expression of genes involved in hepatic TG synthesis, and anti-inflammatory activity via GPCR on macrophages

Block 4 Pharm (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions